Compare WOLF & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | VIR |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.3M | 773.5M |
| IPO Year | 1993 | 2019 |
| Metric | WOLF | VIR |
|---|---|---|
| Price | $18.45 | $5.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $10.50 | ★ $25.73 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $759,700,000.00 | $16,860,000.00 |
| Revenue This Year | $14.86 | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.05 | $4.16 |
| 52 Week High | $36.60 | $14.45 |
| Indicator | WOLF | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 42.12 |
| Support Level | $17.02 | $6.49 |
| Resistance Level | $18.49 | $6.75 |
| Average True Range (ATR) | 1.37 | 0.48 |
| MACD | -0.29 | -0.09 |
| Stochastic Oscillator | 21.77 | 18.63 |
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.